IceCure Medical (NASDAQ:ICCM) Issues Quarterly Earnings Results

IceCure Medical (NASDAQ:ICCM) announced its quarterly earnings results on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01, Yahoo Finance reports. IceCure Medical had a negative return on equity of 77.41% and a negative net margin of 535.84%. The business had revenue of $1.26 million during the quarter. During the same period in the prior year, the business earned ($0.11) EPS.

IceCure Medical Price Performance

ICCM stock traded down $0.01 during midday trading on Friday, reaching $1.24. The company had a trading volume of 75,478 shares, compared to its average volume of 544,469. The stock has a 50 day moving average price of $1.30 and a 200-day moving average price of $1.07. IceCure Medical has a 1-year low of $0.52 and a 1-year high of $1.57. The company has a quick ratio of 3.41, a current ratio of 4.03 and a debt-to-equity ratio of 0.03.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new position in IceCure Medical in the second quarter valued at about $78,000. UBS Group AG grew its position in IceCure Medical by 1,302.3% in the fourth quarter. UBS Group AG now owns 28,986 shares of the company’s stock valued at $45,000 after acquiring an additional 26,919 shares during the last quarter. Bank of America Corp DE grew its position in IceCure Medical by 57.2% in the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock valued at $86,000 after acquiring an additional 20,159 shares during the last quarter. Finally, Boothbay Fund Management LLC grew its position in IceCure Medical by 100.0% in the fourth quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock valued at $62,000 after acquiring an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 0.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ICCM. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of IceCure Medical in a report on Thursday. Alliance Global Partners lifted their target price on IceCure Medical from $1.90 to $2.90 and gave the stock a “buy” rating in a report on Wednesday, March 20th.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.